, Volume 27, Issue 12, pp 991–1004 | Cite as

Cost Effectiveness of Herpes Zoster Vaccine in Canada

  • Mehdi Najafzadeh
  • Carlo A. MarraEmail author
  • Eleni Galanis
  • David M. Patrick
Original Research Article


Background: Herpes zoster (HZ), or shingles, results from reactivation of latent varicella zoster virus in the sensory ganglia of adults, and results in significant morbidity in the elderly, including the development of postherpetic neuralgia (PHN). The lifetime risk of HZ is about 20–30% and the incidence increases with age. The protective effect of the HZ vaccine has been shown in a large clinical trial; however, the effectiveness of the vaccine decreased with age of vaccination.

Objective: We sought to compare the incremental cost and health benefits of HZ vaccine over status quo (no HZ vaccine) from the perspective of the Canadian healthcare payer.

Methods: We developed a discrete-event simulation model comparing the costs and QALYs accrued to patients receiving HZ vaccine to those who did not. The effect of the vaccine on the (i) incidence of severe, moderate or mild HZ; (ii) severity and duration of HZ; (iii) incidence of PHN among patients with HZ; (iv) duration of PHN; and (v) costs associated with treating HZ and PHN were modelled. Data from published literature, including the Shingle Prevention Study, were used for transition probabilities. Health resource utilizations were estimated using administrative data retrieved from the British Columbia Medical Services Plan and hospital separation databases in British Columbia from 1994 to 2003. Utility estimates were obtained from various published sources. Canadian 2008 costs were used and both cost and QALYs were discounted at a 5% annual rate in the base-case analyses.

Results: On average, receiving the vaccination lowered mean direct medical costs (excluding the vaccine costs) by $Can35 per person. The incremental cost and QALYs per person receiving the vaccine versus no vaccination were $Can115 and 0.0028 QALYs, respectively, resulting in an incremental cost-effectiveness ratio of $Can41 709 per QALY gained for a cohort of elderly subjects aged ≥60 years. Results were robust in probabilistic and univariate sensitivity analyses. Expected value of perfect information was estimated at $Can47.72 per person, reflecting the expected monetary losses that could be avoided by having perfect information on all model parameters.

Conclusion: HZ vaccination of adults, especially for individuals aged 60–75 years, seems to be a cost-effective intervention and might be considered by Canadian decision makers.


Herpes Zoster Varicella Zoster Virus Human Papilloma Virus Vaccine Varicella Zoster Virus Infection Vaccine Cost 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This study was part of work done by Carlo Marra as a consultant to the British Columbia Centre for Disease Control to evaluate the cost effectiveness of herpes zoster vaccine in British Colombia. The authors have no conflicts of interest that are directly relevant to the content of this study.

Supplementary material

40273_2012_27120991_MOESM1_ESM.pdf (103 kb)
Supplementary material, approximately 106 KB.


  1. 1.
    Brisson M, Edmunds WJ, Law B, et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect 2001; 127: 305–14PubMedCrossRefGoogle Scholar
  2. 2.
    Edgar BL, Galanis E, Kay C, et al. The burden of varicella and zoster in British Columbia 1994-2003: baseline assessment prior to universal vaccination. Can Commun Dis Rep 2007; 33: 1–15PubMedGoogle Scholar
  3. 3.
    Dworkin RH, Portenoy RK. Pain and its persistence in herpes zoster. Pain 1996; 67: 241–51PubMedCrossRefGoogle Scholar
  4. 4.
    Pellissier JM, Brisson M, Levin MJ. Evaluation of the costeffectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine 2007; 25: 8326–37PubMedCrossRefGoogle Scholar
  5. 5.
    Oster G, Harding G, Dukes E, et al. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain 2005; 6: 356–63PubMedCrossRefGoogle Scholar
  6. 6.
    Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352: 2271–84PubMedCrossRefGoogle Scholar
  7. 7.
    Brisson M, Van de Velde N, De Wals P, et al. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 2007; 25: 5399–408PubMedCrossRefGoogle Scholar
  8. 8.
    De Wals P, Coudeville L, Trottier P, et al. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis. Vaccine 2007; 25: 5433–40PubMedCrossRefGoogle Scholar
  9. 9.
    Rohan P. Vaccines and Related Biological Products Advisory Committee. FDA clinical briefing document for Merck & Co., Inc. Zoster vaccine live (Oka/Merck), Zostavax® [online]. Available from URL: ( [Accessed 2009 Sep 2]
  10. 10.
    Levin MJ, Barber D, Goldblatt E, et al. Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: duration of booster effect. J Infect Dis 1998; 178: S109–12CrossRefGoogle Scholar
  11. 11.
    Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 2001; 19: 3076–90PubMedCrossRefGoogle Scholar
  12. 12.
    Johnson JA, Pickard AS. Comparison of the EQ-5D and SF-12 health surveys in a general population survey in Alberta, Canada. Med Care 2000; 38: 115–21PubMedCrossRefGoogle Scholar
  13. 13.
    Petrou S, Hockley C. An investigation into the empirical validity of the EQ-5D and SF-6D based on hypothetical preferences in a general population. Health Econ 2005; 14: 1169–89PubMedCrossRefGoogle Scholar
  14. 14.
    Brisson M, Pellissier JM, Camden S, et al. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia. Hum Vaccin. Epub 2008 Jan 25; 4 (3)Google Scholar
  15. 15.
    Statistics Canada. Life tables, Canada, provinces and territories, reference period: 2000 to 2002. Catalogue no. 84-537-XIE [online]. Available from URL: ( [Accessed 2009 Sep 2]
  16. 16.
    Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies: Canada. 3rd ed., 2006 [online]. Available from URL: ( [Accessed 2009 Sep 2]Google Scholar
  17. 17.
    McDonough CM, Grove MR, Tosteson TD, et al. Comparison of EQ-5D, HUI, and SF-36-derived societal health state values among spine patient outcomes research trial (SPORT) participants. Qual Life Res 2005; 14: 1321–32PubMedCrossRefGoogle Scholar
  18. 18.
    Hornberger J, Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Int Med 2006; 145: 317–25PubMedGoogle Scholar
  19. 19.
    Dworkin RH, White R, O’Connor AB, et al. Healthcare costs of acute and chronic pain associated with a diagnosis of herpes zoster. J Am Geriatr Soc 2007; 55: 1168–75PubMedCrossRefGoogle Scholar
  20. 20.
    Regier DA, Sunderji R, Lynd LD, et al. Cost-effectiveness of self-managed versus physician-managed oral anticoagulation therapy. CMAJ 2006; 174: 1847–52PubMedCrossRefGoogle Scholar
  21. 21.
    Balen RM, Marra CA, Zed PJ, et al. Cost-effectiveness analysis of enoxaparin versus unfractionated heparin for acute coronary syndromes: a Canadian hospital perspective. Pharmacoeconomics 1999; 16 (5 Pt 2): 533–42PubMedCrossRefGoogle Scholar
  22. 22.
    Statistics Canada. The consumer price index. Catalogue no. 62-001-X, table 81 [online]. Available from URL: ( [Accessed 2008 Dec 1]
  23. 23.
    Government of British Columbia, Ministry of Health. Medical Services Commission payment schedule. April 2008 [online]. Available from URL: ( [Accessed 2009 Mar 20]Google Scholar
  24. 24.
    Rothberg MB, Virapongse A, Smith KJ. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis 2007; 44: 1280–8PubMedCrossRefGoogle Scholar
  25. 25.
    Halpern EF, Weinstein MC, Hunink MG, et al. Representing both first- and second-order uncertainties by Monte Carlo simulation for groups of patients. Med Decis Making 2000; 20: 314–22PubMedCrossRefGoogle Scholar
  26. 26.
    Brennan A, Kharroubi S, O’Hagan A, et al. Calculating partial expected value of perfect information via Monte Carlo sampling algorithms. Med Decis Making 2007; 27: 448–70PubMedCrossRefGoogle Scholar
  27. 27.
    Sadatsafavi M, Najafzadeh M, Bansback N, et al. A novel method for the calculation of the expected value of partial perfect information. 30th Annual Meeting of the Society for Medical Decision Making; 2008 Oct 19–22; PhiladelphiaGoogle Scholar
  28. 28.
    Hammerschmidt T, Goertz A, Wagenpfeil S, et al. Validation of health economic models: the example of EVITA. Value Health 2003; 6: 551–9PubMedCrossRefGoogle Scholar
  29. 29.
    Goldman GS. Cost-benefit analysis of universal varicella vaccination in the U.S. taking into account the closely related herpes-zoster epidemiology. Vaccine 2005; 23: 3349–55PubMedCrossRefGoogle Scholar
  30. 30.
    Brisson M, Edmunds WJ. Varicella vaccination in England and Wales: cost-utility analysis. Arch Dis Child 2003; 88: 862–9PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  • Mehdi Najafzadeh
    • 1
  • Carlo A. Marra
    • 1
    • 4
    Email author
  • Eleni Galanis
    • 2
  • David M. Patrick
    • 2
    • 3
  1. 1.Collaboration for Outcomes Research and Evaluation (CORE), Faculty of Pharmaceutical SciencesUniversity of British ColumbiaVancouverCanada
  2. 2.Epidemiology ServicesBC Centre for Disease ControlVancouverCanada
  3. 3.Department of Healthcare and EpidemiologyUniversity of British ColumbiaVancouverCanada
  4. 4.Centre for Health Evaluation and Outcome Sciences (CHEOS)VancouverCanada

Personalised recommendations